Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Exelixis, Inc.    EXEL

EXELIXIS, INC.

(EXEL)
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

Exelixis: Phase 3 Combination Study for Melanoma Didn't Meet Primary Endpoint

share with twitter share with LinkedIn share with facebook
share via e-mail
0
06/20/2019 | 05:22pm EDT

By Josh Beckerman

Exelixis said a Phase 3 drug trial evaluating the combination of cobimetinib and atezolizumab to treat melanoma didn't meet its primary endpoint of progression-free survival.

Exelixis discovered cobimetinib, which was approved in the U.S. in 2015 and is co-promoted by Roche Holding Genentech unit. Atezolizumab was developed by Genentech.

The safety profile observed in the IMspire170 trial was consistent with the known safety profiles of the individual drugs, Exelixis said.

Genentech, the sponsor of the trial, plans to present results at an upcoming medical meeting.

Exelixis shares fell 6.5% to $19.77 after hours.

Write to Josh Beckerman at josh.beckerman@wsj.com

Stocks mentioned in the article
ChangeLast1st jan.
EXELIXIS, INC. -3.89% 21.27 Delayed Quote.8.13%
ROCHE HOLDING -2.36% 265 Delayed Quote.13.37%
ROCHE HOLDING LTD. -0.14% 245.6 Delayed Quote.14.10%
ROCHE HOLDING LTD. -2.42% 264.65 Delayed Quote.11.42%
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on EXELIXIS, INC.
07/17EXELIXIS : to Release Second Quarter 2019 Financial Results on Wednesday, July 3..
BU
07/15EXELIXIS : Updates Phase 1b COSMIC-021 Trial of Cabozantinib in Combination With..
BU
06/20EXELIXIS, INC. : Regulation FD Disclosure (form 8-K)
AQ
06/20EXELIXIS : Phase 3 Combination Study for Melanoma Didn't Meet Primary Endpoint
DJ
05/29EXELIXIS : Announces Webcasts of Investor Conference Presentations in June 2019
BU
05/23EXELIXIS, INC. : Material Modification to Rights of Security Holders, Submission..
AQ
05/16EXELIXIS : and Iconic Therapeutics Enter into Exclusive Option and License Agree..
BU
05/14EXELIXIS : Announces Webcasts of Investor Conference Presentations on May 21, 20..
BU
05/14EXELIXIS' : Collaborator Daiichi Sankyo Launches MINNEBRO Tablets in Japan
AQ
05/13EXELIXIS : rsquo; Collaborator Daiichi Sankyo Launches MINNEBRO® (Esaxerenone) T..
BU
More news
Financials (USD)
Sales 2019 919 M
EBIT 2019 350 M
Net income 2019 301 M
Finance 2019 1 124 M
Yield 2019 -
P/E ratio 2019 22,3x
P/E ratio 2020 17,5x
EV / Sales2019 5,76x
EV / Sales2020 4,48x
Capitalization 6 419 M
Chart EXELIXIS, INC.
Duration : Period :
Exelixis, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends EXELIXIS, INC.
Short TermMid-TermLong Term
TrendsBullishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 14
Average target price 29,62  $
Last Close Price 21,27  $
Spread / Highest target 112%
Spread / Average Target 39,2%
Spread / Lowest Target 3,43%
EPS Revisions
Managers
NameTitle
Michael M. Morrissey President, Chief Executive Officer & Director
Stelios B. Papadopoulos Chairman
Christopher J. Senner Chief Financial & Accounting Officer, Executive VP
Gisela M. Schwab Chief Medical Officer & President-Medical Affairs
Peter Lamb Chief Scientific Officer & EVP-Scientific Strategy
Sector and Competitors
1st jan.Capitalization (M$)
EXELIXIS, INC.8.13%6 419
GILEAD SCIENCES3.98%82 702
VERTEX PHARMACEUTICALS7.47%44 598
REGENERON PHARMACEUTICALS-20.18%32 544
GENMAB14.94%11 908
SAREPTA THERAPEUTICS INC36.77%11 068